Androgen Receptor

AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses

17 views | Jan 09 2024

"Our study reveals that the AURKA inhibitor MLN8237 enhances the effectiveness of immunotherapy in tumor cells by upregulating PD-L1 expression, presenting a promising approach to augmenting anti-tumor responses and potentially overcoming drug resistance in targeted therapy." [Read the Full Post]

Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response

9 views | Nov 25 2023

The study suggests that proxalutamide, an androgen receptor antagonist, has the potential to prevent SARS-CoV-2 infection, inhibit multiple variants, protect against cytokine-induced lung damage, and may yield promising clinical outcomes pending ongoing phase 3 trials. [Read the Full Post]

Novel vesicular and particulate drug delivery systems for topical treatment of acne

11 views | Oct 27 2023

The utilization of vesicular and particulate drug delivery systems in topical antiacne treatment shows promise in minimizing side effects while maintaining efficacy, offering a novel approach to improve patient outcomes. [Read the Full Post]

Acetylation regulates the nucleocytoplasmic distribution and oncogenic function of karyopherin alpha 2 in lung adenocarcinoma

95 views | Sep 18 2023

The acetylation of KPNA2 by CBP/p300 promotes cytosolic localization and suppresses its oncogenic activity in lung cancer cells. [Read the Full Post]

Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics

22 views | Jun 15 2023

Advancements in the diagnosis and management of metastatic hormone-sensitive prostate cancer (mHSPC), including improved imaging techniques, germline multigene testing, and the integration of multiple agents, have significantly enhanced patient care and outcomes in the last decade. [Read the Full Post]

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care

24 views | Jun 15 2023

This article reviews the phase-three data on triplet therapy for metastatic castrate-sensitive prostate cancer (mCSPC), addresses knowledge gaps, discusses implementation challenges, and proposes a treatment selection algorithm for clinicians. [Read the Full Post]

Targeting androgen receptor degradation with PROTACs from bench to bedside

30 views | May 16 2023

Recent advances in the development of small-molecule PROTAC AR degraders have shown promising clinical efficacy in the treatment of prostate cancer, overcoming resistance mechanisms and improving current therapies. [Read the Full Post]

An overview of PROTACs: a promising drug discovery paradigm

49 views | May 16 2023

PROTAC technology has emerged as a promising therapeutic approach due to its ability to target "undruggable" proteins and induce complete protein degradation, but further research and development are needed to optimize its efficacy and overcome its limitations. [Read the Full Post]

HOW TO OPTIMALLY SEQUENCE AVAILABLE THERAPY LINES IN ADVANCED PROSTATE CANCER

40 views | Apr 08 2023

The optimal sequencing of available therapy lines for advanced prostate cancer should be individualized based on several factors and decided in collaboration with the patient and their healthcare team. [Read the Full Post]

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer

47 views | Mar 21 2023

This study suggests that genetic variations in CYP17A1 and other androgen-related genes may help predict the efficacy and toxicity of abiraterone acetate treatment in advanced prostate cancer patients. [Read the Full Post]